Rothschild & Co has initiated coverage on West Pharmaceutical Services Inc (WST) with a Buy rating, effective September 14, 2025. This marks the firm's first assessment of the company, reflecting its research on the business and industry dynamics.
West Pharmaceutical Services, headquartered in Exton, Pennsylvania, specializes in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment provides elastomers and primary containment, drug delivery devices, and analytical lab services, primarily for biologic and pharmaceutical customers. The Contract-Manufactured Products segment focuses on designing and manufacturing complex devices for various medical applications.
As of now, WST trades at $268.37, with a market capitalization of $19.8 billion. The company has a P/E ratio of 40.29 and an EPS of 6.75. Upcoming earnings are scheduled for July 22, 2026, with an EPS estimate of $1.97 and revenue expected at $823.8 million.
Analyst ratings serve as professional opinions based on extensive research. While they can offer valuable insights, they are based on assumptions that may not always hold true. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst views are just one component of a comprehensive investment strategy.